1. In Vivo

Deals Shaping the Medical Industry, September 2016

 
• By Beth Allan, Steven Muntner, Maureen Riordan, and Deanna Kamienski

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2016.

Bio-Techne Corp. paid $250mm cash to acquire privately held molecular pathology firm Advanced Cell Diagnostics Inc. (ACD). The deal could also include up to $75mm in earn-outs. (Aug.)

The deal marks Bio-Techne's foray into the genomics field. ACD develops and sells genomic analysis consumables for its RNA in situ hybridization technology RNAscope. The platform allows for the detection and monitoring of single RNA molecules and biomarkers at the single-cell level, with applications in the diagnostics and companion testing markets. Products include assay kits and reagents, target probes, and software, which together brought in $25mm in revenues for the company for the last twelve months

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

More from In Vivo

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.